3SOF

Im sorry but i feel u made a big mistake. The money is coming from the govy.They didnt pay for research to not buy.Also look at angn and acor on the charts.After the long white candlestick off the rebound they had 1 day like this then took off.JMHO,Good luck all.

Quote from: etercnoc on November 08, 2006, 07:16:14 PM
Im sorry but i feel u made a big mistake. The money is coming from the govy.They didnt pay for research to not buy.Also look at angn and acor on the charts.After the long white candlestick off the rebound they had 1 day like this then took off.JMHO,Good luck all.

I beg to differ on this issue.  David had a game plan and he followed his game plan limiting his loss.  For all we know, this stock could tank tomorrow and we'll be the ones looking like a fool .  You never know in the world of the stock market.  Anything can/will happen no matter how strong your feelings are! 

I agree with you however that the comparison between ACOR and SIGA look very similar even up to the day after a nice long white candle.  I'm just hoping that we can see the same white candlestick tomorrow   

Good luck all!

Thai

Yea , i understand. Im sorry i was not trying to disrespect anyones opinion.I guess i should have worded my statement differently.Hope we all can smile from making money  and we will see what siga and the market brings us in the AM.Have a good evening.

Bought some more @ 4.02$.

I wonder when they are going to announce that 'little' contract, it's almost a week now?!



SIGA Passes Another Milestone with Smallpox Drug SIGA-246
Thursday November 9, 1:17 pm ET

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the successful results of two independent primate trials of its smallpox drug SIGA-246. Last month, SIGA announced that SIGA-246 provides complete protection against human smallpox virus in nonhuman primates. The current trials involve infection with high doses of monkeypox virus, which may be lethal in primates if left untreated. SIGA-246 again afforded complete protection against disease symptoms. As with the primate trial last month and the human safety trial announced earlier this year, the current trials also demonstrate that SIGA-246 should be safe as well as effective.

ADVERTISEMENT
The first monkeypox virus study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) and conducted at the Lovelace Respiratory Research Institute in Albuquerque, NM. In this study, all monkeys in the two groups receiving SIGA-246 (different dosages) were completely protected from disease.

The second study was conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and was funded by the Department of Defense's Defense Threat Reduction Agency under the supervision of Dr. John Huggins, Chief of the Viral Therapeutics Branch. In the second study, two groups of nonhuman primates received SIGA-246 orally starting either one day post-infection or three days post-infection. Again both treatment groups were completely protected from disease.

"Taken together with the recent breakthrough results from the smallpox virus study, the data continue to support the use of SIGA-246 as the first drug available to prevent and treat disease caused by pathogenic poxviruses without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. He added, "These are very important results for two reasons. First, in many respects monkeypox infections in non-human primates are more aggressive than infection with smallpox virus (normally a human pathogen), so protection by SIGA-246 represents a higher hurdle. Second, SIGA will likely use SIGA-246's performance against monkeypox infection in monkeys, along with the results in all of the several animal species tested to date, to satisfy FDA's efficacy requirements, so success here bodes well."

SIGA previously announced that SIGA-246 has been shown to be safe to administer to humans as a once-a-day pill. SIGA-246 has also demonstrated 100% disease protection in several mouse models of infection, which results SIGA will use, along with results from additional tests yet to be completed, to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to SIGA-246.

The Department of Homeland Security has designated smallpox a "material threat" to our national security, so SIGA-246 will be eligible for purchase for the Strategic National Stockpile under Project Bioshield.

In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and LCM), flaviruses (Dengue), and the filoviruses (Ebola and Marburg), each of which presents a substantial, unmet medical need.


http://biz.yahoo.com/bw/061109/20061109005761.html?.v=1





Siga: Studies Show Smallpox Drug Is Safe
Thursday November 9, 2:41 pm ET

Siga Pharamceuticals Says 2 Federal Studies Show Smallpox Drug Is Safe and Effective

NEW YORK (AP) -- Biotechnology company Siga Technologies Inc. said Thursday results from two independent studies of its smallpox drug show that it is safe and effective.

The trials were conducted by the National Institute of Allergy and Infectious Diseases and the U.S. Army Medical Research Institute of Infectious Diseases. They focused on primates that had high levels of monkeypox infection, which can be fatal if left untreated. In both studies, the subjects were completely protected from the disease.

ADVERTISEMENT
The study validates a previous study, the company said, in which the drug candidate provided complete protection against human smallpox in non-human primates.

Studies have shown that the treatment drug is safe to administer to humans in a once-a-day pill form. The drug, called Siga-246, has been granted Fast-Track status by the Food and Drug Administration.

Shares of Siga rose 14 cents, or 3.8 percent, to $4.03 in afternoon trading on the Nasdaq. The stock has traded between 86 cents and $5.50 over the last 52 weeks.


http://biz.yahoo.com/ap/061109/siga_clinical_trial.html?.v=1

Quote from: Se7en on November 09, 2006, 06:30:31 PM
Bought some more @ 4.02$.

I wonder when they are going to announce that 'little' contract, it's almost a week now?!

There it is, not only 1, but 2!!! 

Up 9% in pre-market!



SIGA Announces $2.3 Million in New Contracts with the U.S. Air Force
Friday November 10, 7:30 am ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced receipt of two contracts from the U.S. Air Force for a total of $2.3 million. SIGA received a one-year, $1.4 million contract with the Air Force Medical Service for the development of counter-measures against important potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. SIGA also received a one-year, $900,000 contract to aid the USAF Special Operations Command (USAFSOC) in its development of specific anti-viral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the Company's lead smallpox drug.
ADVERTISEMENT


"We appreciate the opportunity to continue the development of these critical biological defense capabilities with our colleagues from the Air Force," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.

Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding.

SIGA recently announced a breakthrough in its SIGA-246 program with the successful completion of a preliminary primate trial in which the drug completely prevented smallpox disease.



http://biz.yahoo.com/bw/061110/20061110005112.html?.v=1

man this stock has volume...and is very volatile intraday....yesterday i got some at 4.03 i sold for now premarket 4.35 ...8% i have to take in this short period as it is the way i do trading. Lets see later what happens ? heading to 5 dollar ?

I don't know guys, this news that Se7en published isn't all that relevant, after all it is a $2.3 M deal in a $140 M market cap (at least according to the latest share count, but it can be higher now).

But I really don't know what to think of this stock, as I said, it allows you to dream, but it is also very risky, since it has no fundamental base to it. Just speculation here, so, at least in the short term, anything can happen.

Longer term I doubt it will sustain current prices.

Good luck 

Quote from: David Randolph on November 10, 2006, 08:16:12 AM
But I really don't know what to think of this stock, as I said, it allows you to dream, but it is also very risky, since it has no fundamental base to it. Just speculation here, so, at least in the short term, anything can happen.

..........just daytrading this ...not staying in for long....i seems a lot of traders are in there....

I got in @ 3.82 yesterday... SIGA is in a strong uptrend trend, if it can close above $3.92 this session we might see above $5.50 next week...

I'm trading SIGA based purely on technicals

Quote from: Terliso on November 10, 2006, 11:39:19 AM
I got in @ 3.82 yesterday... SIGA is in a strong uptrend trend, if it can close above $3.92 this session we might see above $5.50 next week...

I'm trading SIGA based purely on technicals

i am joining you terlisa am back in 4.04 ...waited for a dip

cool beans...I waited too and bought in at $4.06.

I like the close above $4.00 and the weekly chart as well. 

consolidation after the contract announcement
13 EMA as support

chart update:

Chart Update:

are we going to see a gap up tomorrow?  possibly $5???  I hope so!


LONDON, Nov 14 (Reuters) - British vaccine maker Acambis Plc (ACM.L: Quote, Profile, Research) said on Tuesday it had been unexpectedly dropped from consideration by the U.S. government for a new smallpox vaccine contract that analysts believe could be worth up to $1 billion.

Acambis shares plunged as much as 37 percent in early trading to a six-year low of 97-1/4 pence.

Acambis had been competing with Denmark's Bavarian Nordic (BAVA.CO: Quote, Profile, Research) to supply the U.S. government with a weakened version of the smallpox vaccine suitable for vulnerable members of the population such as the elderly.


THE 21st CENTURY IN PICTURES

War and Conflict
View Slideshow
At 0830 GMT, Bavarian Nordic shares were up 20.5 percent at 494 Danish crowns. Bavarian Nordic was not immediately available for comment.

"We are surprised that the U.S. government would eliminate Acambis from the ... process," Acambis Chief Executive Gordon Cameron said in a statement. "We believe that our proposal would have met the requirements of the U.S. government, especially given Acambis' track record in the biodefence field."

Acambis had already supplied the U.S. government with more than $500 million worth of standard smallpox vaccine as the country moved to build up stocks amid fears of bio-terrorist attack. Analysts had assumed Acambis would win at least half of the new contract. "This is obviously a significant disappointment," Goldman Sachs analysts wrote in a research note. "In our view, management credibility has suffered a significant setback and highlights the imperative of strategic alternatives."

Acambis said it had been informed that its proposal for the new contract was "no longer in the competitive range for award".

"Acambis plans to request a meeting to gain further clarification, following which it will consider its options," the firm said. (additional reporting by Michael Flaherty in New York and Kyle McLaughlin in Copenhagen)

Well the Acambis news was out Before market Tuesday morning. 

UPDATE 3-Acambis loses U.S. smallpox deal, shares slump
Tue Nov 14, 2006 6:21am ET146

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061114:MTFH47811_2006-11-14_11-21-42_L14654127&type=comktNews&rpc=44